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Nutrient sensingThe hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP) are
secreted after a meal. Like other enteroendocrine hormones they help to orchestrate the bodies' response
to the availability of newly absorbable nutrients and are noteworthy as they stimulate postprandial insulin
secretion, underlying what is known as the incretin effect. GLP-1-mimetics are now widely used in the treat-
ment of type 2 diabetes and advantages over older insulinotropic therapies include weight loss. An alterna-
tive treatment regime might be the recruitment of endogenous GLP-1, however, very little is known about
the physiological control of enteroendocrine responses. This review focuses on the molecular mechanisms
to detect nutrient arrival in the gut that have been implicated within the incretin secreting cells.
© 2011 Elsevier Inc. Open access under CC BY license.1. Introduction
Endocrine cells in the gastrointestinal tract – so called enteroen-
docrine cells – secrete a range of hormones that regulate glucose ho-
meostasis, gut motility, epithelial proliferation, appetite and
adiposity. Two gut peptides, glucose-dependent insulinotropic poly-
peptide (GIP — formerly known as gastric inhibitory polypeptide)
and glucagon-like peptide-1 (GLP-1) are widely recognised for their
role as incretins, and underlie the augmentation of insulin secretion
that is observed when glucose is administered orally rather than in-
travenously [1–3]. The incretin effect has been estimated to account
for 50–70% of total postprandial insulin secretion [3–5], and although
primarily considered as a response to oral glucose, it may also play a
physiological role following lipid ingestion [6].
2. Properties of the incretin hormones
GIP is a 42-amino acid peptide produced by enteroendocrine
K-cells, which are found in highest numbers in the duodenal and jeju-
nal epithelia. It is secreted in response to the intake of fat and glucose
[7], with plasma levels rising by 10–20 fold and reaching a peak just
15–30 min after meal ingestion [8]. GIP has a circulating half-life of
only a few minutes as it is hydrolysed rapidly by the proteolytic en-
zyme dipeptidyl-peptidase 4 (DPPIV) into a truncated and inactive
product [9]. GIP not only has insulinotropic effects on the pancreaticMedical Research, Wellcome
ad, Cambridge, CB2 0XY, UK.
 license.β-cell but is also implicated in lipid metabolism. Expression of the
GIP receptor has been detected on rat [10] and human adipocytes
[11], and it has been found that GIP promotes triglyceride incorpora-
tion into adipose tissue [12–15], although in human volunteers this
was only observed under conditions of hyperglycaemia and did not
signiﬁcantly alter the concentration of circulating triglycerides [12].
Additional evidence demonstrated that GIP can also increase glucose
transport and promote fatty acid synthesis in isolated adipocytes [16].
Others, however, have observed lipolytic effects of GIP, as evidenced
by enhanced release of glycerol from differentiated 3T3-L1 adipo-
cytes [17].
GLP-1 is a product of alternative processing of proglucagon in
enteroendocrine L-cells [18,19], which are found along the length of
the intestinal tract but at highest density in the distal ileum and
colon [20] (Fig. 1). Following food ingestion plasma GLP-1 concentra-
tion rises within minutes and can remain elevated for several hours
[21]. Like GIP, secreted GLP-1 is rapidly inactivated by DPPIV [22]. In
contrast to the obesogenic properties of GIP, GLP-1 has anorexigenic
effects [23]. Exogenous administration of this peptide reduces food
intake not only in healthy normal-weight subjects [24] but also in
obese humans [25]. It also inhibits gastric acid secretion [26,27], de-
celerates gastric emptying [28,29] and suppresses glucagon release
from pancreatic α-cells [30].
Besides their acute insulinotropic effects, the incretin hormones
have additional beneﬁcial effects on the endocrine pancreas. Both
GLP-1 and GIP receptors are expressed on pancreatic alpha and
beta-cells [31–34] and signalling mediated by these structurally dis-
tinct receptors promotes the survival of beta-cell lines [35,36]. Exper-
imental evidence suggests that GLP-1 stimulates beta-cell neogenesis
[37] and proliferation, and promotes cell survival in vitro and in vivo










Fig. 1. Incretin secreting cells. A) Glucose dependent insulinotropic polypeptide (GIP) is secreted from enteroendocrine K-cells found in highest density in the duodenum, whereas
glucagon-like peptide-1 (GLP-1) is secreted from enteroendocrine L-cells found in highest density in the more distal intestine, the ileum and colon. B) K- and L-cells are both “open-
type” cells, making direct contact with the intestinal lumen via their apical microvilli, presumably enabling them to directly assess the content composition. Proximally located cells
are in an ideal position to assess postprandial nutrient availability, whilst stimulation of more distally located cells probably also involves humoral and/or neural signals (arrow in
A). C) Phase contrast image of intestinal cells in a slice through colonic crypts from a mouse transgenic for the yellow ﬂuorescent protein Venus under the control of the
proglucagon-promoter. Venus-ﬂuorescence was excited at 480 nm and the two positive cells in the ﬁeld of view are indicated by the white arrows (photograph by Gareth Rogers).
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crease in the anti-apoptotic bcl-2 gene [40]. These effects potentially
offer an important therapeutic advantage to the incretin hormones
compared with other insulin secretagogues used as anti-diabetic
agents. Moreover, as plasma GLP-1 levels were found to be decreased
in type 2 diabetic patients compared to control non-diabetic subjects
[41], the development of novel anti-diabetic interventions that enhance
endogenous incretin secretion appears an attractive therapeutic strate-
gy. Incretin based therapies are already available for themanagement of
type 2 diabetes. These include the injectable high afﬁnity GLP-1 recep-
tor agonist exenatide, the DPP4 resistant GLP-1 analogue liraglutide
and the orally available DPP4 inhibitors known as the “gliptins”. Speciﬁc















Fig. 2. Current model of L-cell nutrient sensing. Nutrients can be taken up by electrogenic tr
the plasma membrane and triggers action potentials, eventually opening voltage-gated Ca2
vesicles. Alternatively intracellular Ca2+ might be raised downstream of the activation of G
to activate protein kinase C. Strong stimulation of GLP-1 secretion is, however, also seen up
be expected to occur upon stimulation of Gs-coupled receptors such as GPR119 and GPBAR3. Mechanisms underlying incretin hormone secretion
Enteroendocrine K- and L-cells exhibit a polarised morphology,
with an apical surface contacting the gut lumen and a basolateral
membrane in close proximity to the circulatory system. This so-
called “open-type” morphology should enable them to sense dietary
nutrients and non-nutrient substances, present in the intestinal
lumen. In live preparations, enteroendocrine cells are not easily dis-
tinguished from surrounding enterocytes and thus for many years, at-
tempts to study their stimulus sensing pathways were restricted to
the use of perfused intestinal preparations and intestinal model cell
lines such as GLUTag, STC-1 and NCI-H716. Until recently, only a
few studies worked with primary cells, using either partially enriched
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ansport at the apical pole of the cell (e.g. SGLT-1 for glucose). This directly depolarises
+-channels. The subsequent rise in cytosolic Ca2+ triggers fusion of GLP-1 containing
q-coupled receptors (e.g. FFAR2/GPR43 for propionate), which would also be expected
on elevation of cyclic adenosine monophosphate (cAMP), which physiologically would
.
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ment of transgenic mice in which GLP-1 or GIP producing cells are la-
belled with a ﬂuorescent marker has enabled the identiﬁcation of
adult murine L- or K-cell populations in culture, and subsequently
the use of single cell recording techniques for the characterisation of
nutrient sensing mechanisms in these cell types [45,46]. Both primary
L cells and the model GLP-1 secreting cell line GLUTag are electrically
active and nutrient responsive [47–49]. Consistent with ﬁndings from
other endocrine cell types, alterations in membrane potential are
coupled via voltage gated Ca2+ entry to the release of secretory vesi-
cles. All enteroendocrine cell types studied to date are also responsive
to signals that activate G-protein coupled receptors.
4. Nutrient sensing
As both K- and L-cells are open-type cells, it seems likely that both
can directly sense changes in luminal nutrient concentrations. Some
differences between GIP and GLP-1 secretory responses to nutrient
ingestion have, however, been observed and it has been proposed
that GIP secretion requires nutrient absorption,whilst themere presence
of nutrients in the lumen is sufﬁcient to trigger GLP-1 secretion. This no-
tion is at least in part based on observations that patients suffering from
celiac disease or tropical malabsorption, conditions characterised by di-
arrhoea and inefﬁcient intestinal absorption of nutrients, havemarked-
ly diminished postprandial GIP secretion but enhanced or chronically
elevated GLP-1 levels (measured at the time as enteroglucagon)
[50,51]. Similarly, it has been found thatα-glucosidase inhibitors inhibit
GIP, but stimulate GLP-1 secretion [52,53]. Another recent report in rats
found GIP secretion to be more steeply dependent on luminal carbohy-
drate dose thanGLP-1, irrespective ofwhether infusionwas into the du-
odenum or ileum [54]. Whilst this may suggest differences in the
sensing mechanisms of K- and L-cells, many of the above observations
might simply reﬂect the different distribution of these cells along the
length of the gut (see Fig. 1). Any intervention that partially interferes
with nutrient absorption, tends also to shift more nutrients into the dis-
tal intestine where most of the L-cells are found, and could thereby in-
crease GLP-1 release even if the nutrient sensing mechanism of
individual L-cells itself depends on absorption. In the case of glucose,
this is illustrated by the differences between GIP and GLP-1 secretion
upon duodenal infusion of glucose in human volunteers — whilst GIP
secretion was already stimulated by the lowest caloric perfusion rate
and increased dose dependently, the mere presence of luminal glucose
in the duodenum was insufﬁcient to stimulate GLP-1 secretion, which
was only seen at perfusion rates exceeding the duodenal absorption ca-
pacity [55]. Differences in GIP and GLP-1 secretory proﬁles after genetic
or pharmacological intervention should thus always take into account
the difference in K- and L-cell location. To our knowledge all identiﬁed
nutrient sensing mechanisms have been found in both cell types, al-
though some differences in the relative contribution of each pathway
might exist [45].
5. Carbohydrates
Carbohydrates, and glucose in particular, have been the most ex-
tensively investigated nutrients in relation to incretin hormone secre-
tion. The majority of studies agree that glucose is a potent
secretagogue for both GIP and GLP-1. Other carbohydrates may trig-
ger secretion but are reportedly less effective than glucose. Increased
plasma GLP-1 levels have been reported in humans after consump-
tion of glucose but not equivalent portions of complex carbohydrates
in the form of brown rice or barley. In a similar pattern, higher levels
of GIP were elicited following consumption of glucose than a barley
meal [56]. Oral glucose also stimulates GLP-1 secretion more effec-
tively than other monosaccharides such as fructose, although both
have been reported to affect appetite similarly [57]. Elevated blood
glucose is not a major stimulus for incretin secretion, suggestingthat there must be a mechanism for the speciﬁc detection of luminal
glucose. Several molecular “sensors” have been proposed.
5.1. Metabolism and KATP channel modulation
Initial studies on the mechanisms involved in glucose sensing by
enteroendocrine cells were conducted on the model cell line GLUTag.
Patch clamp experiments showed that glucose reduced the mem-
brane conductance, depolarised the cell membrane and triggered ac-
tion potentials. These events were accompanied by elevated levels of
intracellular ATP and calcium, and release of GLP-1. Together with the
ﬁnding that the electrical activity could be abolished by addition of
the KATP channel opener, diazoxide, these results suggested an en-
gagement of KATP channels in the stimulatory effects of glucose in
GLUTag cells [49,58]. Contrary to initial concerns that this may be a
cell line artefact, it was subsequently shown that glucose also triggers
electrical activity and enhanced GLP-1 secretion in primary cultures
of mouse colonic L-cells [46]. KATP channel subunits, Kir6.2 and
SUR1 (sulphonylurea receptor), and the rate limiting glycolytic en-
zyme, glucokinase, have been detected in GLUTag cells [49] and pri-
mary K and L cells from mouse [45,46] or human [59] by
quantitative RT-PCR or immunohistochemical analysis. Although ini-
tial work on a subclone of STC-1 cells failed to detect GIP secretion
in response to glucose [60], studies on mixed epithelial cultures iso-
lated frommouse duodenum demonstrated glucose and KATP channel
dependent GIP release [45].
Although KATP channels are undoubtedly present and functional in
K and L cells, as demonstrated in vitro, closure of these channels is not
primarily responsible for linking glucose ingestion to GIP or GLP-1 se-
cretion in vivo. This is supported by the ﬁnding that mice lacking the
Kir6.2 subunit of KATP channels exhibited increased rather than re-
duced levels of GIP secretion in response to an oral glucose load
[61]. In humans, the sulphonylurea glibenclamide, which inhibits
KATP channels in β-cells and as a result stimulates insulin release,
does not change the levels of GLP-1 or GIP secretion following an
oral glucose tolerance test [62]. An analogous conclusion was reached
by Pearson et al., who also demonstrated that basal and glucose stim-
ulated levels of GLP-1 and GIP were not different between diabetic
patients with mutations in the gene encoding Kir6.2, KCNJ11, and
healthy control subjects. It is important to note, however, that these
patients suffered from neonatal diabetes, characterised by hypergly-
caemia resulting from defective sensitivity of β-cell KATP channels to
ATP inhibition which impairs insulin secretion [63].
5.2. Metabolism independent mechanisms
Given the evidence above, KATP channel closure in response to in-
creased glucose metabolism cannot be exclusively responsible for
glucose sensing by K and L cells further emphasised by the fact that
the non-metabolisable sugars alpha-methyl-glucopyranoside and 3-
O-methylglucose have been reported to stimulate GIP and GLP-1 se-
cretion both in vitro and in vivo [45,46,64–66]. Some groups have,
thus, postulated that neither metabolism nor uptake is necessary for
sugar detection, and that intestinal glucose sensing mirrors lingual
sweet taste perception [67]. Two G protein coupled receptors,
known as Tas1R2 and Tas1R3, form a heterodimeric sweet taste recep-
tor which recognises glucose and other natural and synthetic sweet-
eners. Upon ligand activation, a pathway involving alpha-gustducin is
stimulated, resulting in stored Ca2+ release and subsequent activation
of the transient receptor potential channel, TRPM5 [68,69]. Expression
of the sweet taste receptor, together with key elements of the signalling
pathway such as alpha-gustducin, PLCβ2 and TRPM5, have been
reported in human and mouse small intestine and colon [70,71], and
colocalisation of alpha-gustducin with the peptides GLP-1 and PYY has
been demonstrated immunohistochemically in human L-cells [72–74].
These ﬁndings triggered the formulation of a new theory implicating
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and L-cells, supported by reports that GLP-1 releasewas stimulated by a
range of sweet substances in GLUTag and NCI-H716 cells [74,75] and
that alpha-gustducin or Tas1R3 knock-out mice exhibited reduced
GLP-1 responses to oral glucose [76]. This theory, however, remains
controversial and has been challenged recently by a number of groups.
In contrast to experiments in cell lines, studies in healthy humans have
shown a lack of effect of sucralose on GLP-1 or GIP secretion [73,77,78],
and in type 2 diabetic patients GLP-1 or GIP levels remained unaltered
after consumption of the non-caloric sweetener, stevioside [79]. Similar
conclusions were reached in in vivo experiments in rodents [80].
Interestingly, the non-metabolisable sugar analogues that trigger
incretin secretion are substrates for sodium/glucose co-transporter-
1 (SGLT1), which is responsible for the active uptake of a variety of
sugars across the small intestinal brush border membrane. Sugars
that are not substrates for SGLT1, such as 2-deoxy-D-glucose and N-
acetyl-D-glucosamine, by contrast, did not alter GLP-1 release [81].
Further evidence implicating SGLT1 as a component of the glucose-
sensing mechanism derives from the ﬁnding that the SGLT1 inhibitor
phloridzin reduced glucose triggered incretin secretion both in vitro
and in vivo [82–84]. Glucose transport via SGLT1 is a tightly regulated
process requiring the contransportartion of two Na+ ions per glucose
molecule [85]. The role of SGLT1 in glucose sensing mechanism was
investigated in the GLUTag cell line where it was demonstrated that
the electrogenicity of this transporter induces a glucose-dependent
inward current sufﬁcient to depolarise the cell membrane and trigger
action potentials [82] (Fig. 2). In GLUTag cells, a high concentration of
alpha-methyl-glucopyranoside (100 mM) was necessary to trigger
GLP-1 release [82], but in primary cultures much lower concentra-
tions were found to be sufﬁcient, the EC50 being 0.2 mM, which is
close to the transport Km of heterologously expressed SGLT1
[46]. The importance of SGLT1 driven glucose uptake for incretin
secretion was recently emphasised by the absence of GLP-1
and GIP-responses to oral glucose in global SGLT-1 knock-out
mice [86], although deﬁnitive proof of a direct action of the trans-
porter within enteroendocrine cells has to await a more targeted
ablation.
6. Lipids
It is well known that fat is a good stimulant for both GIP and GLP-1
secretion [8,87,88]. The response appears to be proportional to the ca-
loric content of the ingested lipid, as secretion is highly sensitive to
dose ﬂuctuations [89,90]. In addition to meal size, secretion of the
two hormones is affected by the degree of fatty acid saturation,
since secretion of GLP-1 in vitro was shown to be preferentially trig-
gered by long chain monounsaturated fatty acids compared with
their saturated equivalents [91]. A superior stimulatory effect of un-
saturated fatty acids has also been described in humans, as olive oil,
which is rich in monounsaturated fatty acids, was found to be more
potent in inducing GIP and GLP-1 secretion than butter, which con-
sists mainly of saturated fat [92].
Although fat is reportedly the most effective nutrient stimulus for
GIP secretion in humans, carbohydrates may play a more important
role in animals such as rodents and pigs [93]. Ingested triglycerides
are hydrolysed by pancreatic lipase into free fatty acids and 2-
monoglycerides [94]. Liberation of these products is a key event pre-
ceding secretion of a number of gut peptides including GIP and GLP-1.
This is evident from studies using the lipase inhibitor, Orlistat, which
has inhibitory effects on postprandial secretion of GIP [95] and GLP-1
[95,96], although the diminution of the latter is not unanimously ac-
cepted [97].
During the last decade, free fatty acids amongst other nutrients,
hormones and neurotransmitters have been reported to act as ligands
for G-protein coupled receptors (GPCR). Thus, previously orphan
GPCRs such as GRP40 (now renamed to free fatty acid receptor 1,FFAR1), GPR41 (FFAR3), GPR43 (FFAR2) and GPR120 have now
been demonstrated to be activated by free fatty acids. This discovery
led to the assumption that these receptors might be modulators of
incretin hormone release, and might, therefore, be promising novel
therapeutic targets for diabetes.
GPR120 has been identiﬁed in the intestine, principally in K and L-
cells [45,46]. Its activation by unsaturated long-chain free fatty acids
such as α-linoleate, docosahexaenoeate, palmitoleate and oleate,
dose-dependently promoted the secretion of GLP-1 both in vitro
and in vivo [98]. Enteroendocrine L and K-cells also express high
levels of the related GPCR, FFAR1 [45,46], which serves as a sensor
of saturated and unsaturated long-chain fatty acids and has been im-
plicated in the secretion of incretin hormones. Engagement of FFAR1
in the secretory responses is demonstrated by the impaired release of
GIP and GLP-1 in FFAR1−/− mice during consumption of a high fat
diet [99]. Since both GPR120 and FFAR1 are coupled to Gq family pro-
teins, their activation is accompanied by stimulation of PKC and IP3-
induced calcium release from the endoplasmic reticulum, although
other mechanisms have been proposed [100]. According to recent re-
ports, of all the mammalian PKC isozymes, PKC zeta is essential for
GLP-1 secretion by long chain unsaturated fatty acids [101]. This par-
ticular PKC isozyme is not sensitive to DAG and Ca2+ and might thus
be recruited independent of Gq-activation.
Short chain fatty acids such as acetic acid (C2:0), propionic acid
(C3:0) and butyric acid (C4:0) are ligands for FFAR2 and FFAR3.
The highest expression of these two receptors has been observed
in the large intestine [102], which is also the site of synthesis of
short chain fatty acids by bacterial fermentation of dietary ﬁbre.
FFAR2 couples to Gq and Gi proteins whilst FFAR3 activates mainly
the Gi/o family [103]. Immunostaining has revealed speciﬁc
expression of FFAR2 in GLP-1 containing L-cells of the human
and rat colon [104]. Activation of FFAR2 resulted in acute Ca2+-res-
ponses in primary mouse L-cells, whereas short chain fatty acid
dependent GLP-1 secretion was abolished in FFAR2 knock-out mice
[105].
To the list of GPCRs, which may function as intestinal lipid sensors
coupled to incretin release, should be added GPR119. This is another
receptor showing speciﬁc expression in K and L-cells along the intes-
tinal tract [45,46,106], and its pharmacological activation by synthetic
small-molecule agonists enhanced GLP-1 and GIP levels in mice [106].
One proposed physiological ligand for GPR119 is oleoylethanolamide
[107], a lipid amide synthesised in the small intestine during diges-
tion of dietary fat [108]. A more recently identiﬁed GPR119 ligand is
2-oleoylglycerol, thus potentially establishing this receptor as a
more general sensor of ingested lipid, as 2-monoacylglycerol is a
standard intermediate of intestinal triglyceride digestion [109]. In
contrast to the FFAR-family, GPR119 is coupled to Gs rather than
Gq, and its activation is therefore accompanied by stimulation of ade-
nylyl cyclase and production of intracellular cAMP [110].
Free fatty acids and monoglycerides are absorbed by the entero-
cytes and re-synthesised into triglycerides in the endoplasmic
reticulum [111]. The procedure involves sequential esteriﬁcation
catalysed by the enzymes monoacylglycerol acyltransferase (MGAT)
and diacylglycerol acyltransferase (DGAT). The newly synthesised
triglycerides are incorporated into chylomicrons, a step controlled
by the microsomal triglyceride transfer protein (MTP) before being
secreted into the lymph. It has been suggested that chylomicron
formation in the small intestine may be associated with the control
of gut peptide secretion. This notion is supported by evidence
reporting diminished GIP levels following administration of pluronic
L81, an inhibitor of chylomicron formation [112]. Furthermore, mice
deﬁcient in MGAT2 or DGAT1 displayed reduced GIP release in
response to an oral triglyceride load, whilst GLP-1 responses were en-
hanced in the DGAT1−/− mice [113]. A metabolically unstable MTP
inhibitor, developed to inhibit intestinal but not hepatic MTP, has
been reported to elevate GLP-1 secretion in rats on a high fat diet,
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ways coupling intracellular metabolism of lipids to GIP and GLP-1 se-
cretion have not yet been established and it remains to be seen
whether the observed discrepancy between either GLP-1 and GIP re-
sponses in the DGAT1 knock-out mice or GLP-1 and CCK responses
after pharmacological MTP inhibition simply reﬂect enhanced delivery
of lipids to the more distal gut.
7. Proteins
Although the ﬁnal steps of dietary protein hydrolysis and absorp-
tion take place in the small intestine, the role played by protein or in-
dividual amino acids in triggering incretin secretion remains an area
of controversy. In humans, for example, protein-rich meals were inef-
fective in altering post-prandial GIP levels [56,115] whereas intraduo-
denal infusion of mixed amino acids [116,117] or oral consumption of
the amino acid glutamine [118] was found to increase GIP release. In
animals such as dogs and rats, peptones are considered as potent
stimuli for GIP release [119,120]. Similarly, not all groups have con-
ﬁrmed a link between protein rich meals and GLP-1 secretion
[54,121]. As for GIP release, a requirement for protein digestion
seems likely, as the enteroendocrine cell lines NCI-H716 [122], STC-
1 and GLUTag [123] secrete GLP-1 in response to meat hydrolysates,
which consist primarily of mixtures of di- and tri-peptides. The
amino acid glutamine has also been found to trigger GLP-1 secretion
in normal weight and obese human subjects [118].
The primary mechanisms underlying detection of amino acids or
small peptides in enteroendocrine cells remain uncertain, as a range
of potential signalling pathways have been postulated. Activation of
the ERK1/2 MAPK and p38 MAPK pathway has been observed in
NCI-H716 cells treated with meat hydrolysate or mixtures of essential
amino acids [124], and may provide a link to GLP-1 release. Gluta-
mine promotes the secretion of GLP-1 from rodent primary cultures
and GLUTag cells via two pathways. Electrogenic Na+ coupled
amino acid uptake appears responsible for initiating membrane depo-
larisation and voltage gated Ca2+ entry, whilst a second pathway in-
volves elevation of intracellular cAMP levels [48]. Synergy between
these Ca2+ and cAMP signalling pathways seems a particularly potent
stimulus of GLP-1 release in vitro. The diversity of electrogenic uptake
mechanisms for amino acids and dipeptides across the intestinal epi-
thelium, together with the range of G-protein coupled receptors now
believed to respond to speciﬁc groups of amino acids or small pep-
tides, may provide enteroendocrine cells with a broad repertoire of
potential sensors of digested protein (Tolhurst et al. 2011 Handbook
of Experimental Pharmacology 209, Appetite Control, in the press, Ref
to be updated once on pubmed).
8. Conclusion
Luminal nutrients trigger incretin secretion through interaction
with a number of different receptors on K- and L-cells. For glucose,
it now appears clear that electrogenic uptake through SGLT1 is the
primary mechanism coupling GLP-1 secretion to the appearance of
glucose in the intestinal lumen. The enteroendocrine cells in this re-
spect appear blind to blood glucose variation simply due to the tar-
geting of SGLT1 to the apical membrane. One prerequisite of this
mechanism is that the cells have a relatively low resting membrane
conductance, as the currents associated with electrogenic nutrient
transport are much smaller than currents achieved by the opening
of voltage- or ligand gated ion channels. It would be interesting to es-
tablish where exactly on an L-cell sodium- and calcium-carried action
potentials [47] are initiated and if there is a targeting of voltage gated
sodium channels to an area near the apical membrane making a
structure analogous to the axon hillock.
Whilst electrogenic nutrient uptake can initiate incretin secretion
by elevating cytosolic Ca2+ through voltage gated Ca2+-channelactivation, more sustained responses are seen when other second
messenger pathways are also recruited. Fatty acids seem clearly to ac-
tivate Gq-coupled receptors, although the secretory responses ob-
served with fatty acids in isolation are fairly moderate and are
unlikely to explain entirely the incretin secretory response observed
following lipid ingestion. Strong stimulation of GIP and GLP-1 secretion
is seen in response to elevation of intracellular cAMP. Gs-coupled recep-
tors like GPR119, which has now been implicated in triglyceride sens-
ing, might thus be important targets in therapeutic stimulation of
GLP-1 release. Other Gs-coupled receptors, like GPBAR/TGR5, which is
not directly sensitive to nutrients, but is activated by bile acids [125],
are likely to play a role in the incretin responses seen after nutrient
ingestion and should also provide additional targets for therapeutic
stimulation of GLP-1 release.
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